Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates
© 2021. The Author(s)..
Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nature communications - 12(2021), 1 vom: 04. Nov., Seite 6393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costa-Verdera, Helena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha-Glucosidases |
|---|
| Anmerkungen: |
Date Completed 27.12.2021 Date Revised 27.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-021-26744-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332753905 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332753905 | ||
| 003 | DE-627 | ||
| 005 | 20231225220228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-021-26744-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332753905 | ||
| 035 | |a (NLM)34737297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costa-Verdera, Helena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2021 | ||
| 500 | |a Date Revised 27.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a alpha-Glucosidases |2 NLM | |
| 650 | 7 | |a EC 3.2.1.20 |2 NLM | |
| 700 | 1 | |a Collaud, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Riling, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Sellier, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Nordin, Jayme M L |e verfasserin |4 aut | |
| 700 | 1 | |a Preston, G Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Cagin, Umut |e verfasserin |4 aut | |
| 700 | 1 | |a Fabregue, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Barral, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Moya-Nilges, Maryse |e verfasserin |4 aut | |
| 700 | 1 | |a Krijnse-Locker, Jacomina |e verfasserin |4 aut | |
| 700 | 1 | |a van Wittenberghe, Laetitia |e verfasserin |4 aut | |
| 700 | 1 | |a Daniele, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Gjata, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Cosette, Jeremie |e verfasserin |4 aut | |
| 700 | 1 | |a Abad, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Simon-Sola, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Severine |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Crosariol, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Antrilli, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Quinn, William J |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Gross, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Boyer, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Anguela, Xavier M |e verfasserin |4 aut | |
| 700 | 1 | |a Armour, Sean M |e verfasserin |4 aut | |
| 700 | 1 | |a Colella, Pasqualina |e verfasserin |4 aut | |
| 700 | 1 | |a Ronzitti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Mingozzi, Federico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 12(2021), 1 vom: 04. Nov., Seite 6393 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:04 |g month:11 |g pages:6393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-021-26744-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 04 |c 11 |h 6393 | ||